M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech BioSpaceEli Lilly plans to use BioArctic's technology to shuttle an undisclosed drug candidate into the brain.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) BioSpace Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. Neuroscience Read full story Post navigation Previous: Boehringer advances duo for aggressive cancers into phase 3Next: AbbVie climbs post-Allergan M&A peak with Apogee buy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026